HeartSciences Inc.: Form 10-Q for the period ended Jul 31, 2023
Filed with the SEC on Sep 14, 2023 and accepted by EDGAR at Sep 14, 2023, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-05-01 to 2023-07-31 | $565.6k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-05-01 to 2023-07-31 | $765.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-05-01 to 2023-07-31 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-05-01 to 2023-07-31 | $36.3k | us-gaap:InterestExpense |
| Net income | 3 months2023-05-01 to 2023-07-31 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-05-01 to 2023-07-31 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-05-01 to 2023-07-31 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-05-01 to 2023-07-31 | 10,331,505 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-05-01 to 2023-07-31 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-05-01 to 2023-07-31 | $4.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-07-31 | $575.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-07-31 | $2.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-07-31 | $2.6m | us-gaap:Assets |
| Current liabilities | At period end2023-07-31 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-07-31 | $3.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-07-31 | −$519.7k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-048168. Last ingested by Listed: Nov 2, 2026, 08:01 ET. Listed shows no prices and gives no investment advice.